Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 58,394 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62. Following the completion of the transaction, the director owned 1,727,293 shares in the company, valued at approximately $1,260,923.89. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $34,533.36.
- On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $121,148.64.
- On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $39,025.71.
- On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $69,650.76.
- On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total transaction of $45,849.00.
Werewolf Therapeutics Stock Down 4.6%
Shares of HOWL traded down $0.03 during trading hours on Monday, hitting $0.69. The company had a trading volume of 199,935 shares, compared to its average volume of 410,071. The firm has a market cap of $33.53 million, a price-to-earnings ratio of -0.51 and a beta of 0.41. The business has a fifty day moving average of $0.81 and a 200-day moving average of $0.88. Werewolf Therapeutics, Inc. has a 12 month low of $0.53 and a 12 month high of $2.38.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.75.
Get Our Latest Stock Analysis on HOWL
Institutional Investors Weigh In On Werewolf Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Renaissance Technologies LLC grew its position in Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after buying an additional 221,766 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Werewolf Therapeutics during the third quarter worth approximately $304,000. Vanguard Group Inc. grew its position in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after buying an additional 109,796 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Werewolf Therapeutics during the second quarter worth approximately $113,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Articles
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
